We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+12.73%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$362M
AUM Growth
-$26.1M
Cap. Flow
-$33.3M
Cap. Flow %
-9.19%
Top 10 Hldgs %
27.18%
Holding
180
New
35
Increased
46
Reduced
71
Closed
24

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$4.86M
2
NRIX icon
Nurix Therapeutics
NRIX
+$3.76M
3
IVA
Inventiva
IVA
+$3.75M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$3.21M
5
DFTX
Definium Therapeutics
DFTX
+$3.15M

Top Sells

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$7.08M
2
COGT icon
Cogent Biosciences
COGT
+$5.16M
3
RVMD icon
Revolution Medicines
RVMD
+$5.14M
4
CDTX
Cidara Therapeutics
CDTX
+$5.06M
5
ACLX
Arcellx
ACLX
+$4.89M

Sector Composition

Rank Sector Weight
1 Healthcare 66.93%
2 Technology 9.01%
3 Industrials 5.47%
4 Consumer Discretionary 2.89%
5 Financials 2.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LITE icon
51
Lumentum
LITE
$57B
$2.19M 0.6%
3,117
-1,200
-28% -$659K
TNGX icon
52
Tango Therapeutics
TNGX
$4.65B
$2.18M 0.6%
+104,193
New +$1.45M
V icon
53
Visa
V
$682B
$2.16M 0.6%
7,141
+850
+14% +$273K
GH icon
54
Guardant Health
GH
$20.7B
$2.16M 0.6%
23,357
-13,401
-36% -$1.35M
HPE icon
55
Hewlett Packard
HPE
$60.7B
$2.14M 0.59%
89,981
+13,800
+18% +$306K
ASMB icon
56
Assembly Biosciences
ASMB
$531M
$2.07M 0.57%
+74,735
New +$2.13M
CIEN icon
57
Ciena
CIEN
$53B
$2.05M 0.57%
5,285
+100
+2% +$30.6K
JAZZ icon
58
Jazz Pharmaceuticals
JAZZ
$15.5B
$2.05M 0.57%
+10,838
New +$1.89M
STOK icon
59
Stoke Therapeutics
STOK
$1.81B
$2.04M 0.56%
62,617
-52,922
-46% -$1.74M
CMPS
60
Compass Pathways
CMPS
$1.67B
$2.01M 0.56%
364,360
-134,573
-27% -$905K
FLS icon
61
Flowserve
FLS
$8.75B
$1.83M 0.51%
24,958
– –
IMCR icon
62
Immunocore
IMCR
$1.78B
$1.77M 0.49%
58,697
+25,699
+78% +$831K
OLMA icon
63
Olema Pharmaceuticals
OLMA
$1B
$1.75M 0.48%
117,601
-123,888
-51% -$2.76M
NATL icon
64
NCR Atleos
NATL
$3.5B
$1.75M 0.48%
+40,100
New +$1.66M
XPO icon
65
XPO
XPO
$25.2B
$1.74M 0.48%
8,923
-3,800
-30% -$681K
ON icon
66
ON Semiconductor
ON
$34B
$1.73M 0.48%
+28,000
New +$1.76M
AVGO icon
67
Broadcom
AVGO
$1.76T
$1.73M 0.48%
5,599
-40
-0.7% -$13.2K
KOD icon
68
Kodiak Sciences
KOD
$2.67B
$1.66M 0.46%
+43,569
New +$1.13M
CEG icon
69
Constellation Energy
CEG
$90.1B
$1.61M 0.44%
5,752
+940
+20% +$286K
CLH icon
70
Clean Harbors
CLH
$16.4B
$1.59M 0.44%
5,543
-700
-11% -$191K
GOOG icon
71
Alphabet (Google) Class C
GOOG
$4.22T
$1.57M 0.43%
5,477
-800
-13% -$251K
CRM icon
72
Salesforce
CRM
$140B
$1.55M 0.43%
8,313
-300
-3% -$62.2K
CORZ icon
73
Core Scientific
CORZ
$6.66B
$1.55M 0.43%
103,412
+39,900
+63% +$681K
ETR icon
74
Entergy
ETR
$52.8B
$1.52M 0.42%
13,528
+3,200
+31% +$322K
CELC icon
75
Celcuity
CELC
$4.31B
$1.5M 0.41%
13,105
-3,438
-21% -$375K
1 2
3
4 5

Similar funds

RWM
Revisor Wealth Management Akron, Ohio $362M AUM 15.97% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MSL
MILLINGTON SECURITIES, LLC Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
BHBT
Burke & Herbert Bank & Trust Alexandria, Virginia $362M AUM 20.5% 1-Year Est. Return
CAP
Cordoba Advisory Partners New York $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return

HighVista Strategies's Q1 2026 Portfolio in Review

As of Q1 2026, HighVista Strategies held 180 positions worth $362M, down 6.7% from $388M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

HighVista Strategies withdrew a net $33.3M in Q1 2026, closing 24 positions and reducing 71 holdings. Its most notable exit was Cidara Therapeutics, an estimated $5.06M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 70% a quarter earlier, followed by Technology and Industrials.

Against the trend, HighVista Strategies opened a new position in Nurix Therapeutics worth $3.51M.

  • HighVista Strategies's largest Q1 2026 buy was Nurix Therapeutics: 226,546 shares worth $3.51M.
  • HighVista Strategies added most to Abivax in Q1 2026, an estimated $4.86M increase.
  • HighVista Strategies's biggest Q1 2026 reduction was Viridian Therapeutics, cutting an estimated $7.08M.
  • HighVista Strategies fully exited Cidara Therapeutics in Q1 2026, selling an estimated $5.06M.
  • HighVista Strategies's ten largest holdings make up 27% of its $362M portfolio in Q1 2026.
  • HighVista Strategies opened 35 new positions and closed 24 in Q1 2026.
  • HighVista Strategies's portfolio value fell 6.7% quarter-over-quarter to $362M.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.